Loading clinical trials...
Loading clinical trials...
A Single Center, Prospective, Blinded Study to Evaluate the Efficacy and Safety of a Tripeptide/Hexapeptide Topical When Used With Er:YAG Hybrid Laser for the Treatment of Acne Scars
To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University of Rochester Medical Center
Rochester, New York, United States
Start Date
February 13, 2020
Primary Completion Date
June 18, 2021
Completion Date
June 18, 2021
Last Updated
April 13, 2023
10
ACTUAL participants
Hybrid fractional laser
DEVICE
Alastin Regenerating Skin Nectar with TriHex Technology
OTHER
Cetaphil face cream
OTHER
Lead Sponsor
University of Rochester
NCT05597267
NCT04827680
NCT05600075
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions